Skip to main content
. 2019 Aug 25;60(2):188–197. doi: 10.1002/jcph.1513

Figure 3.

Figure 3

Model‐predicted median percent inhibition of ex vivo IL‐6–induced pSTAT3 and IL‐7–induced pSTAT5 by immediate‐release regimens of upadacitinib and 5 mg of tofacitinib after 14 days of twice‐daily administration. IL, interleukin; pSTAT3, phosphorylation of signal transducer and activator of transcription proteins 3.